Evidence map›Paper›PMID 30165490›Full record

ReviewInflammatory bowel diseases2019

Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.

Tamara Pérez-Jeldres, Christopher J Tyler, Joshua D Boyer, Thangaraj Karuppuchamy, Giorgos Bamias, Parambir S Dulai, Brigid S Boland, William J Sandborn, Derek R Patel, Jesús Rivera-Nieves

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Review
  8. Article
  9. Article
  10. Understanding the therapeutic toolkit for inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tamara Pérez-JeldresInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Christopher J TylerInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Joshua D BoyerInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Thangaraj KaruppuchamyInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Giorgos BamiasGI Unit, 3rd Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens, Greece.
Parambir S DulaiInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Brigid S BolandInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
William J SandbornInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Derek R PatelInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.
Jesús Rivera-NievesInflammatory Bowel Disease Center, Division of Gastroenterology, University of California San Diego, La Jolla, CA, USA.

Funding

UC San Diego Clinical and Translational Research InstituteKL2TR001444 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEPP, COLIN A. · 2015 to 2024
$15.4M
Novel Traffic-targeted Therapies for IBDR01DK108670 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2016 to 2020
$3.3M
Immunoprofiling for identifying biomarkers in celiac diseaseR21AI149636 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ERNST, PETER B., RIVERA-NIEVES, JESUS · 2020 to 2021
$433k
High Dimensional Mass Cytometry Analysis of the Effects of Vedolizumab in Intestinal Cellular Subsets and its Correlation with Clinical ParametersR21DK118927 · NIDDK · VETERANS MEDICAL RESEARCH FDN/SAN DIEGO · PI RIVERA-NIEVES, JESUS · 2019 to 2020
$392k
BLRD VA I01 BX003436NCATS NIH HHS KL2 TR001444NIAID NIH HHS R21 AI149636NIDDK NIH HHS R01 DK108670NIDDK NIH HHS R21 DK118927
6 · The paper itself

Abstract

After 20 years of successful targeting of pro-inflammatory cytokines for the treatment of IBD, an alternative therapeutic strategy has emerged, based on several decades of advances in understanding the pathogenesis of IBD. The targeting of molecules involved in leukocyte traffic has recently become a safe and effective alternative. With 2 currently approved drugs (ie, natalizumab, vedolizumab) and several others in phase 3 trials (eg, etrolizumab, ozanimod, anti-MAdCAM-1), the blockade of trafficking molecules has firmly emerged as a new therapeutic era for IBD. We discuss the targets that have been explored in clinical trials: chemokines and its receptors (eg, IP10, CCR9), integrins (eg, natalizumab, AJM300, vedolizumab, and etrolizumab), and its endothelial ligands (MAdCAM-1, ICAM-1). We also discuss a distinct strategy that interferes with lymphocyte recirculation by blocking lymphocyte egress from lymph nodes (small molecule sphingosine-phosphate receptor [S1PR] agonists: fingolimod, ozanimod, etrasimod, amiselimod). Strategies on the horizon include additional small molecules, allosteric inhibitors that specifically bind to the active integrin form and nanovectors that allow for the use of RNA interference in the quest to modulate pro-inflammatory leukocyte trafficking in IBD.

Indexed as

AnimalsCell MovementGastrointestinal AgentsHumansInflammatory Bowel DiseasesLeukocytesGastrointestinal Agents

Identifiers

PMID30165490
PMCPMC6327230

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.